GSK Nov 2024 44.000 call
| Previous close | 1.7000 |
| Open | 1.7000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 44.00 |
| Expiry date | 2024-11-15 |
| Day's range | 1.7000 - 1.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Evening StandardFTSE 100 Live 1 May: GSK, Next and Smith & Nephew in focus, shares edge up before Fed call
Upgraded profit guidance by GSK stood out today in a session featuring updates by Next, Smith & Nephew and Sensodyne business Haleon. The quartet all signalled robust trading at the start of 2024, helping the FTSE 100 index to begin May in resilient fashion. Traders are also looking ahead to tonight’s US Federal Reserve decision and whether September is still the most likely month for the first cut.
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
